The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.

摘要: Although distant metastases occur in a minority of papillary thyroid carcinoma (PTC) patients, their impact on disease course and survival rates is profound, with aggregate 10-yr 40% (1). Limited treatment options further complicate management metastatic PTC. Radioiodine (RAI) remains the standard care for most Of particular concern, however, significant prevalence PTC unable to trap RAI; such are termed RAI-refractory (RAIR). Because cancer loses differentiated features normal tissue, one feature commonly lost sodium iodide symporter expression, which entire basis use RAI therapy malignancies. This phenomenon can heterogeneous manner: given patient, uptake vary between individual metastases, it even within metastasis at cellular level.